Explore › Outcome › Serum creatinine
Outcome

Serum creatinine

Also known as: Creatinine - serum Creatinine measurement, serum Creatinine measurement, serum (procedure) Serum creatinine Serum creatinine (& level) Serum creatinine (& level) (procedure) Serum creatinine NOS Serum creatinine NOS (procedure) Serum creatinine elevation
3 findings 1 paper 3 related entities View in graph →

Related entities

interventions
Fenofibrate1
conditions
Cardiovascular Disease1
studys
PMC45096011

Findings (27)

None
adverse

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Size: Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%
PMC4509601
Finding details → · Paper → · Graph →
None
adverse

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Size: Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%
PMC4509601
Finding details → · Paper → · Graph →
None
adverse

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Size: Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%
PMC4509601
Finding details → · Paper → · Graph →
None
adverse

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Size: Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%
PMC4509601
Finding details → · Paper → · Graph →
None
adverse

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Size: Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%
PMC4509601
Finding details → · Paper → · Graph →
None
adverse

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Size: Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%
PMC4509601
Finding details → · Paper → · Graph →
None
adverse

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Size: Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%
PMC4509601
Finding details → · Paper → · Graph →
None
adverse

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Size: Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%
PMC4509601
Finding details → · Paper → · Graph →
None
adverse

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Size: Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%
PMC4509601
Finding details → · Paper → · Graph →
None
adverse

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Size: Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%
PMC4509601
Finding details → · Paper → · Graph →
None
adverse

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Size: Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%
PMC4509601
Finding details → · Paper → · Graph →
None
adverse

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Size: Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%
PMC4509601
Finding details → · Paper → · Graph →
None
adverse

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Size: Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%
PMC4509601
Finding details → · Paper → · Graph →
None
adverse

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Size: Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%
PMC4509601
Finding details → · Paper → · Graph →
None
adverse

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Size: Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%
PMC4509601
Finding details → · Paper → · Graph →
None
adverse

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Size: Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%
PMC4509601
Finding details → · Paper → · Graph →
None
adverse

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Size: Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%
PMC4509601
Finding details → · Paper → · Graph →
None
adverse

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Size: Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%
PMC4509601
Finding details → · Paper → · Graph →
None
adverse

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Size: Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%
PMC4509601
Finding details → · Paper → · Graph →
None
adverse

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Size: Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%
PMC4509601
Finding details → · Paper → · Graph →
None
adverse

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Size: Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%
PMC4509601
Finding details → · Paper → · Graph →
None
adverse

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Size: Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%
PMC4509601
Finding details → · Paper → · Graph →
None
adverse

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Size: Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%
PMC4509601
Finding details → · Paper → · Graph →
None
adverse

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Size: Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%
PMC4509601
Finding details → · Paper → · Graph →
None
adverse

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Size: Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%
PMC4509601
Finding details → · Paper → · Graph →
None
adverse

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Size: Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%
PMC4509601
Finding details → · Paper → · Graph →
None
adverse

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Size: Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%
PMC4509601
Finding details → · Paper → · Graph →

Papers (1)